Story thread · 3 reports / 2 sources
Edesa Biotech Announces Proposed Public Offering
financialpost.com · 9h · first report
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warrants to purchase common shares in lieu thereof) and accompanying common share […]
The coverage
- Edesa Biotech prices $25M public offering at $5.50 per share
investing.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.